In the search for faster and more sensitive cancer diagnostic techniques, imaging combined with AI has proven most sucessful and is in clinical use. There are a wide range of other technollgies in various stages of development between lab and clinical trials. The objective of CDT23 to review cancer diagnostic technologies other than imaging: liquid and breath biopsy, biomarkers in urine, biosensor technology. Recognising the innovation pathway from lab to clinic, the conference will include commercial as well as academic developments.
Liquid biopsy for single and multile biomarkers
Breath biomarkers
Biomarkers in urine and other body fluids
Biosensors for single and multiple biomarkers
AI and data mining
Accelerating pathway from lab to clinic
Submit abstacts
Abstracts are invited for presentations on any of the conference topics.
Please submit a 200 word abstract to cdt23@sensor100.com. Abstracts will be reviewed by the conference organising committee and authors notified with 2 weeks. Deadline for submission: 27th October.
Format
The conference will take place online, to facilitate participation by a global audience. Provisional timing is from 10:00am to 6:00pm each day (GMT).
Sponsored by:
© 2023 All worldwide rights reserved